Axon Enterprise, Inc $AXON Shares Sold by Transcend Capital Advisors LLC

Transcend Capital Advisors LLC cut its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 10.2% during the second quarter, HoldingsChannel reports. The fund owned 613 shares of the biotechnology company’s stock after selling 70 shares during the period. Transcend Capital Advisors LLC’s holdings in Axon Enterprise were worth $508,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in AXON. TCTC Holdings LLC lifted its holdings in Axon Enterprise by 75.0% in the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 24 shares during the last quarter. Banque Transatlantique SA acquired a new position in Axon Enterprise in the first quarter valued at approximately $31,000. Catalyst Capital Advisors LLC acquired a new position in Axon Enterprise during the first quarter worth $32,000. Flaharty Asset Management LLC acquired a new position in Axon Enterprise during the first quarter worth $33,000. Finally, Hemington Wealth Management lifted its stake in Axon Enterprise by 70.8% during the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 17 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Zacks Research cut Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 2nd. Bank of America upped their price target on Axon Enterprise from $895.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Wednesday, August 6th. Northland Securities set a $800.00 price target on Axon Enterprise in a research note on Tuesday, August 5th. Weiss Ratings restated a “hold (c)” rating on shares of Axon Enterprise in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. upped their price target on Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a research note on Thursday, July 17th. Fourteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $841.64.

Axon Enterprise Stock Up 0.8%

Shares of NASDAQ AXON opened at $755.00 on Wednesday. The stock has a market cap of $59.27 billion, a P/E ratio of 186.42, a PEG ratio of 29.09 and a beta of 1.41. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a 12-month low of $422.38 and a 12-month high of $885.91. The business’s fifty day simple moving average is $732.26 and its 200-day simple moving average is $729.18.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.58. The business had revenue of $668.54 million for the quarter, compared to analysts’ expectations of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company’s revenue for the quarter was up 32.6% compared to the same quarter last year. During the same period last year, the firm earned $1.20 earnings per share. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Transactions at Axon Enterprise

In related news, CFO Brittany Bagley sold 5,000 shares of the stock in a transaction on Monday, September 29th. The stock was sold at an average price of $713.88, for a total value of $3,569,400.00. Following the transaction, the chief financial officer owned 93,592 shares of the company’s stock, valued at $66,813,456.96. This represents a 5.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Jeffrey C. Kunins sold 7,891 shares of the stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $750.10, for a total value of $5,919,039.10. Following the completion of the transaction, the insider directly owned 144,538 shares in the company, valued at $108,417,953.80. This trade represents a 5.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 59,932 shares of company stock valued at $45,115,616 over the last ninety days. Company insiders own 5.70% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.